United States: Federal Circuit Establishes Legal Standard For Demonstrating Standing In An Appeal From A Final Written Decision In Inter Partes Review

On January 9, 2017, the United States Court of Appeals for the Federal Circuit ("the Federal Circuit") issued a decision in Phigenix, Inc. v. ImmunoGen, Inc., No. 2016-1544 (Fed. Cir. Jan. 9, 2017) establishing the legal standard for demonstrating standing in an appeal from a final written decision in IPR. In Phigenix, the court disagreed with appellant, and petitioner below, Phigenix, Inc.'s ("Phigenix") position that as a licensor of competing patents it had suffered injury in fact as a result of the PTAB's determination that ImmunoGen, Inc.'s ("ImmunoGen") patents were nonobvious. In denying Phigenix's appeal, the Federal Circuit confirmed that the procedural right granted by 35 U.S.C. § 141(c) does not free an appellant from the standing requirement of Article III. In so doing, the court took the opportunity to elaborate on the legal standard, the burden of production, and the sort of evidence that will meet the burden.

The Phigenix decision was foreshadowed by an earlier decision in Consumer Watchdog.1 There, the Federal Circuit considered an Appellant's standing in an appeal arising from inter partes reexamination. The court determined that although pre-AIA § 315(b) statutorily granted a third-party requestor a procedural right to appeal an agency's action, such a right does not eliminate the requirement that a party have a particularized, concrete stake in the outcome of the action. 573 F.3d at 1262. The Consumer Watchdog court likened the standing requirement in that situation to that of a party seeking declaratory judgment, but with relaxed immediacy and redressability requirements by virtue of the statutory right. Id. Following Consumer Watchdog, it remained unanswered whether the same logic would apply in the context of IPR and § 141(c) until the Phigenix decision.

Phigenix originally petitioned for IPR of ImmunoGen's U.S. Patent No. 8,337,856 ("the '856 patent"), in IPR2014-00676, alleging that certain claims were unpatentable as obvious over various prior art references. In its final written decision, the PTAB concluded that the Asserted Claims were nonobvious, and Phigenix appealed. Before the Federal Circuit, ImmunoGen raised the issue of Phigenix's standing, thereby placing the burden on Phigenix to establish that it had Article III standing by identifying or producing relevant evidence.

In its reply, Phigenix argued that as a patent licensing firm with the rights to a separate patent covering activities related to ImmunoGen's patented cancer drug, Phigenix suffers injury in fact in the form of increased competition. To support this argument, Phigenix introduced two declarations into evidence and an attorney's letter sent to ImmunoGen. The first declaration asserted that ImmunoGen's '856 patent encumbers Phigenix's licensing efforts while ImmunoGen receives millions of dollars in licensing revenue. Phigenix argued "that the most reasonable conclusion is that at least a portion of that licensing revenue would inure to Phigenix if the '856 patent were invalidated." The second declaration was intended to show that "Phigenix had multiple discussions [with ImmunoGen]... through telephone conversations concerning the Phigenix technology and its patent portfolio." And, the attorney letter illustrated Phigenix's belief that the '856 patent is invalid, in order to "underscore[] the actual, concrete controversy" between the parties.

The Phigenix court rejected both Phigenix's arguments and the evidence relied upon, and clarified the standard for establishing injury in fact arising from agency action. First, the court held that in an appeal from an agency action an appellant's burden is the same as that of a plaintiff moving for summary judgment in a district court. Second, the court established what evidence will meet this burden, recognizing two separate situations calling for different evidence: (1) where standing is self-evident, such as in the case where the appellant is the object of the action at issue, the appellant need only identify evidence of record to support its standing, and (2) where no evidence of record exists, because standing was not an issue before the agency, the appellant must present additional evidence to the court "by affidavit or other evidence" "to the extent necessary to explain and substantiate its entitlement to judicial review." Lastly, regarding the timing of such presentation, the court stated that an appellant must produce such evidence "at the earliest possible opportunity," such as in response to a motion to dismiss or in its opening brief.

Reviewing the evidence produced by Phigenix against the requirements of Fed. R. Civ. P. 56(c)(4) and Fed. R. Evid. 901, the court found the declarations to be mere conclusions of law and that the evidence lacked any admissible facts to support Phigenix's hypothetical injury. In reaching this conclusion, the court decision provides some key takeaways. First, the court identified certain situations in which a petitioner-appellant likely would have standing, foremost of which is when appellant is also party to a district court litigation related to the patent. But, the court also implied that, had Phigenix argued "it faces risk of infringing the '856 patent, that it is an actual or prospective licensee of the patent, or that it otherwise plans to take any action that would implicate the patent," then, with the proper evidentiary showing, it would have had standing. This implication comports with the language in Consumer Watchdog likening the relevant standard to a relaxed declaratory judgment Article III analysis. Thus, a demonstration by sufficient evidence that an appellant does, or intends to, commercialize a product reading on a patent surviving IPR, or that a patentee had demanded appellant take a license to such a patent, then such an appellant likely would have standing to appeal the PTAB's final written decision.

Second, the court also pointed out that had Phigenix demonstrated it had licensed its patent to the same parties to which ImmunoGen had licensed the '856 patent, the invalidation of the '856 patent might have increased Phigenix's revenues, and by implication Phigenix's economic harm theory may have held more weight in a standing analysis. But, Phigenix did not introduce any evidence that they had licensed their patent to anyone at all. Thus, the court declined to reject an increased competition in licensing theory outright, but instead focused on the lack of evidence demonstrating such injury in fact. Lastly, the court echoed its Consumer Watchdog decision stating that where a party is not engaged in any activity that could give rise to infringement, the estoppel provisions of § 315 do not constitute an injury in fact, but whether the estoppel provisions could give rise to injury in fact remains to be seen. 2

In conclusion, Phigenix counsels that an appellant from an IPR final written decision – and perhaps any agency action before the Federal Circuit – be prepared early to enter evidence into the record affirmatively establishing injury in fact, and that care be taken to ensure that such evidence comports with both the FRCP and the FRE. The Federal Circuit has provided some direction regarding what form such an injury may take, but the full scope of an injury in fact sufficient to provide standing in an appeal from IPR remains to be garnered from future decisions.


[1] Consumer Watchdog v. Wis. Alumni Research Found., 753 F.3d 1258 (Fed. Cir. 2014).

[2] 753 F.3d at 1263 ("the court, however, leaves it to future panels to decide whether, under other circumstances, the preclusive effect of the estoppel provisions could constitute an injury in fact.").

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.